Barrington Research Reaffirms “Outperform” Rating for Orthofix Medical (NASDAQ:OFIX)

Orthofix Medical (NASDAQ:OFIX)‘s stock had its “outperform” rating reissued by equities researchers at Barrington Research in a report issued on Tuesday,Benzinga reports. They currently have a $18.00 price target on the medical device company’s stock. Barrington Research’s target price would indicate a potential upside of 30.81% from the company’s current price.

A number of other analysts have also commented on OFIX. Stifel Nicolaus initiated coverage on shares of Orthofix Medical in a research note on Tuesday, October 28th. They set a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Finally, TD Cowen assumed coverage on Orthofix Medical in a report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price target on the stock. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $20.00.

Orthofix Medical Price Performance

Shares of NASDAQ:OFIX opened at $13.76 on Tuesday. The company has a market capitalization of $544.90 million, a PE ratio of -4.54 and a beta of 0.78. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.47. The stock has a fifty day moving average of $14.39 and a 200-day moving average of $14.66. Orthofix Medical has a one year low of $10.24 and a one year high of $20.48.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, CFO Julie Andrews sold 4,873 shares of Orthofix Medical stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total value of $70,073.74. Following the completion of the sale, the chief financial officer directly owned 58,039 shares in the company, valued at $834,600.82. The trade was a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Massimo Calafiore sold 9,797 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $15.21, for a total transaction of $149,012.37. Following the transaction, the chief executive officer owned 217,237 shares in the company, valued at $3,304,174.77. This represents a 4.32% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 24,270 shares of company stock valued at $370,958. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Orthofix Medical

Large investors have recently made changes to their positions in the stock. AYAL Capital Advisors Ltd boosted its holdings in Orthofix Medical by 74.7% during the second quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock valued at $10,517,000 after acquiring an additional 403,433 shares during the period. Squarepoint Ops LLC lifted its position in shares of Orthofix Medical by 515.6% during the 2nd quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company’s stock worth $1,312,000 after purchasing an additional 98,552 shares during the last quarter. Engine Capital Management LP boosted its stake in Orthofix Medical by 13.6% during the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after purchasing an additional 510,281 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Orthofix Medical in the 2nd quarter valued at approximately $147,000. Finally, Geode Capital Management LLC increased its position in Orthofix Medical by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 930,252 shares of the medical device company’s stock worth $10,374,000 after buying an additional 64,788 shares during the period. Institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.